A concise review based on analytical methods for estimation of dapagliflozin and linagliptin in pharmaceutical dosage form

Dapagliflozin and linagliptin are two oral antidiabetic drugs that are commonly used in combination to treat type 2 diabetes. Dapagliflozin is a sodium-glucose cotransporter 2(SGLT2) inhibitor that works by increasing the excretion of glucose in the urine. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by increasing the levels of incretin hormones, which stimulate the pancreas to produce more insulin and reduce the production of glucagon. There are a variety of analytical methods that can be used to estimate the concentration of dapagliflozin and linagliptin in dosage forms. These methods include high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS/MS), and high-performance thin-layer chromatography (HPTLC). This review provides an overview of the different analytical methods that have been developed for the estimation of dapagliflozin and linagliptin in pharmaceutical dosage forms. The focus of the review is on the development and validation of these methods, as well as their application to the analysis of pharmaceutical formulations.